secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001193125-25-003549
Event type: litigation
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst settles FIRDAPSE patent suit with Teva; generic entry barred until Feb 2035
--------------------------------------------------------------------------------

- Teva agrees not to market generic FIRDAPSE in the U.S. before February 25, 2035, if FDA approved.
- All ongoing FIRDAPSE patent litigation between Catalyst/SERB and Teva will be terminated.
- Litigation against remaining defendants Hetero (all patents) and Lupin (2037 patent) is ongoing.
- Confidential license agreement to be submitted to FTC and DOJ for review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525003549/0001193125-25-003549-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525003549/d890025d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-003549

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer